T1	Participants 441 484	we report interim data (up to Jan 11, 2013)
T2	Participants 1714 1833	117 randomly assigned patients, 111 were given everolimus between Aug 20, 2009, and Jan 11, 2013 (date of data cutoff);
T3	Participants 750 841	patients with tuberous sclerosis complex who had SEGA that was growing and needed treatment
